Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
O Bjarnadottir, Q Romero, PO Bendahl… - Breast cancer research …, 2013 - Springer
Lipophilic statins purportedly exert anti-tumoral effects on breast cancer by decreasing
proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting
enzyme of the mevalonate pathway, is the target of statins. However, data on statin-induced
effects on HMGCR activity in cancer are limited. Thus, this pre-operative study investigated
statin-induced effects on tumor proliferation and HMGCR expression while analyzing
HMGCR as a predictive marker for statin response in breast cancer treatment. The study was …
proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting
enzyme of the mevalonate pathway, is the target of statins. However, data on statin-induced
effects on HMGCR activity in cancer are limited. Thus, this pre-operative study investigated
statin-induced effects on tumor proliferation and HMGCR expression while analyzing
HMGCR as a predictive marker for statin response in breast cancer treatment. The study was …
以上显示的是最相近的搜索结果。 查看全部搜索结果